MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
Acta Neurochirurgica · 05.10.2024 · 166 (1)
DOI: 10.1007/s00701-024-06300-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neurochirurgica, online erschienen am 05.10.2024. Verfasst von Prajwal Ghimire und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK. prajwal.1.ghimire@kcl.ac.uk. Hauptthemen laut MEDLINE: Glioblastoma, DNA Modification Methylases, Tumor Suppressor Proteins, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) promoter is a valid biomarker for predicting response to therapy with alkylating agents and, independently, prognosis in IDH-wildtype(IDH-w) glioblastoma. We aim to study the impact of its methylation in overall survival of the unresectable IDH-w glioblastoma undergoing biopsy and systemic treatment.
Methods
We collected six-year retrospective (2017–2023) data at a quaternary neurosurgery center for patients undergoing biopsy as the only surgical procedure for an unresectable IDH wildtype glioblastoma. Data was collected from patient records including neuro-oncology multidisciplinary team meeting (MDT) documentation. Patients were grouped into categories according to different types of treatment received after biopsy (no treatment, chemotherapy (CT), radiotherapy (RT), chemoradiotherapy (CRT), chemoradiotherapy with adjuvant temozolomide (CRT with adjuvant TMZ), EORTC-NCIC protocol followed by second line treatment) and according to methylation status (unmethylated (< 5%), borderline methylated (5–15%) and strongly methylated (> 15%)). Survival analysis was performed.
Results
166 glioblastoma IDH wildtype patients were included in the study with mean age of 62.5 years (M: F = 1.5: 1). 70 (49.3%) patients had unmethylated MGMT status (< 5%), 29 (20.4%) patients had borderline methylated MGMT status (5–15%) and 43 (30.2%) patients had methylated MGMT status (> 15%). 36 (25.3%) patients did not receive any treatment post biopsy, 13 (9.1%) received CT only, 27 (19%) RT only, 12 (8.4%) CRT, 33 (23.2%) CRT with adjuvant TMZ, whereas 21 (14.7%) received EORTC-NCIC protocol along with second line treatment. In biopsy only group, there was no notable difference in survival outcomes among the different methylation statuses. For biopsy and any-other-form-of-treatment methylated groups showed a distinct trend of better survival compared to the borderline or unmethylated groups. Overall, methylated patients had better survival as compared to unmethylated or borderline groups.
Conclusion
Methylated MGMT status are predictors for better overall survival in unresectable IDH wildtype glioblastoma patients undergoing biopsy and treatment regardless of the treatment modality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK. prajwal.1.ghimire@kcl.ac.uk.
- Department of Neurosurgery, King's College Hospital, London, UK. prajwal.1.ghimire@kcl.ac.uk.
- Department of Neurosurgery, King's College Hospital, London, UK.
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Zitieren
APA
Ghimire, P., Kamaludin, A., Palau, B. F., Lavrador, J. P., Gullan, R., Vergani, F., Bhangoo, R., & Ashkan, K. (2024). MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study. Acta Neurochirurgica, 166(1). https://doi.org/10.1007/s00701-024-06300-x
Vancouver
Ghimire P, Kamaludin A, Palau BF, Lavrador JP, Gullan R, Vergani F, et al. MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study. Acta Neurochirurgica. 2024;166(1). doi:10.1007/s00701-024-06300-x
BibTeX
@article{Ghimire2024,
author = {Ghimire, Prajwal and Kamaludin, Ahmad and Palau, Berta F and Lavrador, Jose P and Gullan, Richard and Vergani, Francesco and Bhangoo, Ranjeev and Ashkan, Keyoumars},
title = {MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study},
journal = {Acta Neurochirurgica},
year = {2024},
volume = {166},
number = {1},
doi = {10.1007/s00701-024-06300-x}
}
EUVIMED